bazlitoran
toll-like receptor 7-8-9 antagonist
Networked: 4
relevant articles (0 outcomes,
2 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Sullivan, Tim:
2 articles
(01/2017 - 01/2013)
|
| 2. | Chunduru, Srinivas:
1 article
(04/2021)
|
| 3. | Dankó, Katalin:
1 article
(04/2021)
|
| 4. | Fiorentino, David F:
1 article
(04/2021)
|
| 5. | Goyal, Namita A:
1 article
(04/2021)
|
| 6. | Kim, Yoo Jung:
1 article
(04/2021)
|
| 7. | Lees, Kirstin:
1 article
(04/2021)
|
| 8. | Mozaffar, Tahseen:
1 article
(04/2021)
|
| 9. | Sarazin, Jeffrey:
1 article
(04/2021)
|
| 10. | Sarin, Kavita Y:
1 article
(04/2021)
|
Related Diseases
| 1. | Psoriasis (Pustulosis Palmaris et Plantaris)
01/01/2017
- " Forty-six psoriasis patients were randomly assigned to IMO-8400 in four dose levels or placebo for 12weeks. " 01/01/2017
- " IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis." 01/01/2017
- " Several immune modulatory oligonucleotides and small molecular weight compounds, including IMO-3100, IMO-8400, and CPG-52364, that block the interaction between endosomal TLRs and their ligands are under clinical investigation for their effectiveness in the treatment of psoriasis. "
|
| 2. | Dermatomyositis (Dermatopolymyositis)
|
| 3. | Hyperplasia
|
|
Related Drugs and Biologics